EUVIMEDEUVIMED entdecken
Crossref

Impact of interruption of CFTR modulator therapies

Burcu Capraz Yavuz, Ebru Yalcin, Halime Nayir Buyuksahin, Birce Sunman, Ismail Guzelkas, Didem Alboga, Meltem Akgul Erdal, Havva Ipek Demir, Raziye Atan, Nagehan Emiralioglu, Deniz Dogru, Ugur Ozcelik und 1 weitere

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.05.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Burcu Capraz Yavuz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Pulmonology, Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Türkiye. Electronic addr…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel drug therapy targeting the defective cystic fibrosis transmembrane conductance regulator protein has the potential to significantly enhance the quality of life for numerous patients with cystic fibrosis. However, in some countries social insurance does not pay for modulators because these drugs are extremely expensive. This study sought to understand the impact on the health of children whose modulator treatments were interrupted because of legal procedures and delivery processes. Our study identified that the significant increase in percent-predicted forced expiratory volume levels (FEV1) and BMI z-score values associated with modulator therapies decreased sharply with their discontinuation. Significant worsening in FEV1, BMI z-scores, and BW z-scores were detected in the first follow-up visit after therapy discontinuation within 1 month. Eight patients had a reduction of FEV1 of more than 10%. The findings suggest that modulatory treatment continuation is important, and it is crucial that treatment is not interrupted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansMaleFemaleChildChloride Channel AgonistsForced Expiratory VolumeQuinolonesWithholding TreatmentAdolescentQuality of LifeBody Mass Index

Stichwörter der Autor:innen

CFTR modulator drugsCystic fibrosisPseudomonas aeruginosa

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorChloride Channel AgonistsQuinolones

Autor:innen und Institutionen

  • Department of Paediatric Pulmonology, Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Türkiye. Electronic address: burcucapraz@hacettepe.edu.tr.
  • Department of Paediatric Pulmonology, Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Ankara, Türkiye.

Zitieren

APA

Capraz Yavuz, B., Yalcin, E., Nayir Buyuksahin, H., Sunman, B., Guzelkas, I., Alboga, D., Akgul Erdal, M., Demir, H. I., Atan, R., Emiralioglu, N., Dogru, D., Ozcelik, U., & Kiper, N. (2024). Impact of interruption of CFTR modulator therapies. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.05.006

Vancouver

Capraz Yavuz B, Yalcin E, Nayir Buyuksahin H, Sunman B, Guzelkas I, Alboga D, et al. Impact of interruption of CFTR modulator therapies. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.05.006

BibTeX
@article{CaprazYavuz2024,
  author = {Capraz Yavuz, Burcu and Yalcin, Ebru and Nayir Buyuksahin, Halime and Sunman, Birce and Guzelkas, Ismail and Alboga, Didem and Akgul Erdal, Meltem and Demir, Havva Ipek and Atan, Raziye and Emiralioglu, Nagehan and Dogru, Deniz and Ozcelik, Ugur and Kiper, Nural},
  title = {Impact of interruption of CFTR modulator therapies},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.05.006}
}
Kostenlos starten →